2023年臨床腫瘤學(xué)新進(jìn)展學(xué)術(shù)研討會(huì)――

2023年臨床腫瘤學(xué)新進(jìn)展學(xué)術(shù)研討會(huì)――BestofASCO?EventinChina2023會(huì)議日程Program會(huì)議第一天2023年7月11日(Day1,July11,2023)8:00–8:15開(kāi)幕式(OpeningCeremony)CSCO代表：吳一龍教授致辭(OpeningspeechbyProf.Yi-LongWuonbehalfofCSCO)ASCO代表：PeterYu教授致辭(OpeningspeechbyProf.PeterYuonbehalfofASCO)血液腫瘤專場(chǎng)(HematologicMalignancy)主席(Chair)：馬軍(JunMa)、王健民(Jian-MinWang)時(shí)間(Time)題目(Topic)講者(Speaker)8:15–8:40Abstract7005^Confirmatoryopen-label,single-arm,multicenterphase2studyoftheBiTEantibodyblinatumomabinpatients(pts)withrelapsed/refractoryB-precursoracutelymphoblasticleukemia(r/rALL).BiTEantibodyblinatumomab在復(fù)發(fā)/難治性急性前體B淋巴細(xì)胞白血病患者〔r/rALL〕的驗(yàn)證性多中心、開(kāi)放標(biāo)簽的單臂2期研究。糜堅(jiān)青(Jian-QingMi)Abstract7008Randomizedcomparisonofibrutinibversusofatumumabinrelapsedorrefractory(R/R)chroniclymphocyticleukemia/smalllymphocyticlymphoma:ResultsfromthephaseIIIRESONATEtrial.ibrutinib與ofatumumab在復(fù)發(fā)或難治性〔R/R〕慢性淋巴細(xì)胞白血病/小淋巴細(xì)胞淋巴瘤的隨機(jī)比較：來(lái)自RESONATEⅢ期試驗(yàn)的結(jié)果。Abstract7026Resultsofaprospective,randomized,open-labelphase3studyofruxolitinib(RUX)inpolycythemiavera(PV)patientsresistanttoorintolerantofhydroxyurea(HU):theRESPONSEtrial.Ruxolitinib〔RUX〕在羥基脲耐藥或不能耐受的真性紅細(xì)胞增多癥〔PV〕患者的前瞻性、隨機(jī)、開(kāi)放標(biāo)簽的Ⅲ期研究結(jié)果：RESPONSE試驗(yàn)。8:40–8:50專家評(píng)述DiscussionTopic:Acomprehensiveoverviewonmoleculartargetedtherapyforleukemia討論主題：白血病分子靶向治療綜述李建勇(Jian-YongLi)8:50–8:55討論(Q&A)馬軍(JunMa)王健民(Jian-MinWang)李建勇(Jian-YongLi)泌尿系統(tǒng)腫瘤專場(chǎng)1(GenitourinaryCancerSession1)主席(Chair)：葉定偉(Ding-WeiYe)、馬建輝(Jian-HuiMa)時(shí)間(Time)題目(Topic)講者(Speaker)8:55–9:20AbstractLBA2Impactonoverallsurvival(OS)withchemohormonaltherapyversushormonaltherapyforhormonesensitivenewlymetastaticprostatecancer(mPrCa):AnECOG-ledphaseIIIrandomizedtrial.一項(xiàng)ECOG領(lǐng)導(dǎo)的III期隨機(jī)臨床試驗(yàn)：激素敏感的新發(fā)轉(zhuǎn)移性前列腺癌患者〔mPrCa〕接受化療聯(lián)合內(nèi)分泌治療比照單用內(nèi)分泌治療對(duì)于總生存期(OS)的影響。戴波(BoDai)Abstract5003ImmediateversusdeferredinitiationofandrogendeprivationtherapyinprostatecancerpatientswithPSA-onlyrelapse.PSA復(fù)發(fā)的前列腺癌患者接受立即雄激素剝奪治療與延遲雄激素剝奪治療的比較。Abstract5008Phase3,randomized,placebo-controlledtrialoforteronel(TAK-700)plusprednisoneinpatients(pts)withchemotherapy-na?vemetastaticcastration-resistantprostatecancer(mCRPC)(ELM-PC4trial).三期、隨機(jī)、撫慰劑對(duì)照臨床試驗(yàn)〔ELM-PC4試驗(yàn)〕：orteronel(tak-700)聯(lián)合強(qiáng)的松治療未接受過(guò)化療的轉(zhuǎn)移性去勢(shì)抵抗型前列腺癌患者〔mCRPC〕的研究。9:20–9:30專家評(píng)述DiscussionTopic:Feasibilityofcombinedtherapyforpatientswithhormone-sensitiveprostatecancer討論主題：對(duì)激素敏感型前列腺癌患者進(jìn)行聯(lián)合治療的可行性何志嵩(Zhi-SongHe)9:30–9:35討論(Q&A)葉定偉(Ding-WeiYe)馬建輝(Jian-HuiMa)何志嵩(Zhi-SongHe)泌尿系統(tǒng)腫瘤專場(chǎng)2(GenitourinaryCancerSession2)主席(Chair)：周芳堅(jiān)(Fang-JianZhou)、謝曉冬(Xiao-DongXie)時(shí)間(Time)題目(Topic)講者(Speaker)9:35–10:00Abstract5009Nivolumabformetastaticrenalcellcarcinoma(mRCC):Resultsofarandomized,dose-rangingphaseIItrial.Nivolumab治療轉(zhuǎn)移性腎細(xì)胞癌〔mRCC):一項(xiàng)隨機(jī)的關(guān)于劑量調(diào)整的II期臨床研究結(jié)果。姚欣(XinYao)Abstract5011InhibitionofPD-L1byMPDL3280Aandclinicalactivityinptswithmetastaticurothelialbladdercancer(UBC).MPDL3280A抑制PD-L1及其對(duì)轉(zhuǎn)移性膀胱尿路上皮癌患者的臨床作用。Abstract5012Immunomodulatoryactivityofnivolumabinpreviouslytreatedanduntreatedmetastaticrenalcellcarcinoma(mRCC):Biomarker-basedresultsfromarandomizedclinicaltrial.Nivolumab對(duì)經(jīng)治和未治轉(zhuǎn)移性腎細(xì)胞癌的免疫調(diào)節(jié)活性：基于生物標(biāo)志物的隨機(jī)臨床試驗(yàn)結(jié)果。10:00–10:10專家評(píng)述DiscussionTopic:ImmunotherapyforRCC?討論主題：腎癌細(xì)胞免疫治療？王秀問(wèn)(Xiu-WenWang)10:10–10:15討論(Q&A)周芳堅(jiān)(Fang-JianZhou)謝曉冬(Xiao-DongXie)王秀問(wèn)(Xiu-WenWang)10:15-10:30休息Break惡性黑色素瘤專場(chǎng)(MelanomaSession)主席(Chair)：郭軍(JunGuo)、梁軍(JunLiang)時(shí)間(Time)題目(Topic)講者(Speaker)10:30–10:55Abstract9000^Efficacyandsafetyoftheanti-PD-1monoclonalantibodyMK-3475in411patients(pts)withmelanoma(MEL).抗PD-1單抗〔MK-3475〕治療411例黑色素瘤患者的療效和平安性研究結(jié)果。斯璐(LuSi)AbstractLBA9008IpilimumabversusplaceboaftercompleteresectionofstageIIImelanoma:InitialefficacyandsafetyresultsfromtheEORTC18071phaseIIItrial.Ipillimumab與撫慰劑輔助治療III期黑色素瘤術(shù)后患者的III期對(duì)照研究〔EORTC18071〕：初步療效和平安性結(jié)果。Abstract9003^Survival,responseduration,andactivitybyBRAFmutation(MT)statusofnivolumab(NIVO,anti-PD-1,BMS-936558,ONO-4538)andipilimumab(IPI)concurrenttherapyinadvancedmelanoma.抗PD-1單抗nivolumab〔BMS-936558〕聯(lián)合Ipilimumab〔IPI〕治療不同BRAF基因突變狀態(tài)的晚期黑色素瘤患者的生存、療效持續(xù)時(shí)間和活化情況的影響。10:55-11:05專家評(píng)述DiscussionTopic:Adjuvantimmunotherapyforresectablemelanoma?討論主題：可手術(shù)黑色素瘤的輔助免疫治療？張曉實(shí)(Xiao-ShiZhang)11:05-11:10討論(Q&A)郭軍(JunGuo)梁軍(JunLiang)張曉實(shí)(Xiao-ShiZhang)胃腸腫瘤專場(chǎng)1(Gastro–intestinalCancerSession1)主席(Chair)：沈琳(LinShen)、徐建明(Jian-MingXu)時(shí)間(Time)題目(Topic)講者(Speaker)11:10-11:35Abstract4003PhaseIIIstudyofapatinibinadvancedgastriccancer:Arandomized,double-blind,placebo-controlledtrial.阿帕替尼治療晚期胃癌的隨機(jī)、雙盲、撫慰劑對(duì)照的III期臨床研究。張小田(Xiao-TianZhang)Abstract4005RAINBOW:Aglobal,phaseIII,randomized,double-blindstudyoframucirumab(RAM)pluspaclitaxel(PTX)versusplacebo(PL)plusPTXinthetreatmentofmetastaticgastroesophagealjunctionandgastricadenocarcinoma(mGC)followingdiseaseprogressiononfirst-lineplatinum-andfluoropyrimidine-containingcombinationtherapy—EfficacyanalysisinJapaneseandWesternpatient.RAINBOW：一項(xiàng)ramucirumab〔RAM〕比照撫慰劑聯(lián)合紫杉醇治療一線鉑類／氟尿嘧啶失敗的轉(zhuǎn)移性胃食管結(jié)合部或胃腺癌的全球隨機(jī)、雙盲、III期研究——日本與西方人群的療效分析。Abstract4008PhaseIIItrialtocomparecapecitabine/cisplatin(XP)versusXPplusconcurrentcapecitabine-radiotherapyingastriccancer(GC):ThefinalreportontheARTISTtrial.卡培他濱／順鉑〔XP〕比照XP聯(lián)合卡陪他濱同步放療治療胃癌的III期研究：ARTIST的最終結(jié)果匯報(bào)。11:35–11:45專家評(píng)述DiscussionTopic:Anti-angiogenesisforgastriccancer討論主題：胃癌的抗血管生成治療郭偉劍(Wei-JianGuo)11:45–11:50討論(Q&A)沈琳(LinShen)徐建明(Jian-MingXu)郭偉劍(Wei-JianGuo)11:50–14:00 午餐和/或衛(wèi)星會(huì)(Lunchand/orsatellitesymposium)胃腸腫瘤專場(chǎng)2(Gastro–intestinalCancerSession2)主席(Chair)：李進(jìn)(JinLi)、徐瑞華(Rui-HuaXu)時(shí)間(Time)專場(chǎng)(Session)講者(Speaker)14:00–14:25AbstractLBA3CALGB/SWOG80405:PhaseIIItrialofirinotecan/5-FU/leucovorin(FOLFIRI)oroxaliplatin/5-FU/leucovorin(mFOLFOX6)withbevacizumab(BV)orcetuximab(CET)forpatients(pts)withKRASwild-type(wt)untreatedmetastaticadenocarcinomaofthecolonorrectum(MCRC).CALGB/SWOG80405：FOLFIRI/mFOLFOX6聯(lián)合貝伐珠單抗或西妥昔單抗用于KRAS野生型轉(zhuǎn)移性結(jié)直腸腺癌初治患者的III期研究。陳功(GongChen)Abstract3503^Maintenancestrategywithfluoropyrimidines(FP)plusBevacizumab(Bev),Bevalone,ornotreatment,followingastandardcombinationofFP,oxaliplatin(Ox),andBevasfirst-linetreatmentforpatientswithmetastaticcolorectalcancer(mCRC):AphaseIIInon-inferioritytrial(AIOKRK0207).轉(zhuǎn)移性結(jié)直腸癌接受氟化嘧啶〔FP〕/奧沙利鉑/貝伐珠單抗〔Bev〕聯(lián)合的標(biāo)準(zhǔn)一線治療后，F(xiàn)P加Bev或Bev單藥維持治療或不治療：一項(xiàng)III期非劣效性研究〔AIOKRK0207〕。Abstract3504Finalresultsandsubgroupanalysesofthephase3CAIRO3study:Maintenancetreatmentwithcapecitabine+bevacizumabversusobservationafterinductiontreatmentwithchemotherapy+bevacizumabinmetastaticcolorectalcancer(mCRC).III期研究CAIRO3的最終結(jié)果和亞組分析：轉(zhuǎn)移性結(jié)直腸癌接受化療+貝伐珠單抗誘導(dǎo)化療后，卡培他濱+貝伐珠單抗維持治療比照單純觀察。14:25–14:35專家評(píng)述DiscussionTopic:UltimatewordsontheroleofmaintenancetherapyformetastaticCRC討論主題：維持治療在轉(zhuǎn)移性結(jié)直腸癌中的價(jià)值——塵埃落定劉云鵬(Yun-PengLiu)14:35–14:40討論(Q&A)李進(jìn)(JinLi)徐瑞華(Rui-HuaXu)劉云鵬(Yun-PengLiu)胃腸腫瘤專場(chǎng)3(Gastro–intestinalCancerSession3)主席(Chair)：秦叔逵(Shu-KuiQin)、王理偉(Li-WeiWang)時(shí)間(Time)專場(chǎng)(Session)講者(Speaker)14:40-15:00Abstract4000Arandomizeddouble-blindphase2studyofruxolitinib(RUX)orplacebo(PBO)withcapecitabine(CAPE)assecond-linetherapyinpatients(pts)withmetastaticpancreaticcancer(mPC).Ruxolitinib聯(lián)合卡培他濱二線治療轉(zhuǎn)移性胰腺癌的隨機(jī)、雙盲、撫慰劑對(duì)照、II期臨床研究。袁瑛(YingYuan)Abstract4006^STORM:AphaseIIIrandomized,double-blind,placebo-controlledtrialofadjuvantsorafenibafterresectionorablationtopreventrecurrenceofhepatocellularcarcinoma(HCC).STORM研究：索拉非尼用于肝細(xì)胞性肝癌切除或射頻術(shù)后輔助治療的隨機(jī)、雙盲、撫慰劑對(duì)照、III期臨床試驗(yàn)。15:00-15:15專家評(píng)述DiscussionTopic:Moleculartargetedtherapyforpancreaticcancer:realityorjustmyth?討論主題：胰腺癌分子靶向治療：現(xiàn)實(shí)還是神話？MargaretA.Tempero翻譯：王峰(FengWang)15:15-15:20討論(Q&A)秦叔逵(Shu-KuiQin)王理偉(Li-WeiWang)MargaretA.Tempero乳腺癌專場(chǎng)1(BreastCancerSession1)主席(Chair)：江澤飛(Ze-FeiJiang)、宋爾衛(wèi)(Er-WeiSong)時(shí)間(Time)專場(chǎng)(Session)講者(Speaker)15:20–15:45Abstract1017RandomizedphaseIIstudyofweeklypaclitaxelwithorwithoutcarboplatinfollowedbycyclophosphamide/epirubicin/5-fluorouracilasneoadjuvantchemotherapyforstageII/IIIAHER2-negativebreastcancer.每周紫杉醇聯(lián)合或不聯(lián)合卡鉑序貫環(huán)磷酰胺/表阿霉素/5-氟尿嘧啶〔CEF〕新輔助治療II/IIIA期HER2-陰性乳腺癌的II期隨機(jī)試驗(yàn)。王碧蕓(Bi-YunWang)Abstract1005Pathologicalcompleteresponse(pCR)ratesaftercarboplatin-containingneoadjuvantchemotherapyinpatientswithgermlineBRCA(gBRCA)mutationandtriple-negativebreastcancer(TNBC):ResultsfromGeparSixto.含卡鉑的新輔助化療治療BRCA突變?nèi)橄侔┗蛉幮匀橄侔┑牟±硗耆徑饴省瞤CR〕：GeparSixto試驗(yàn)結(jié)果。Abstract1019^Cisplatinwithorwithoutrucaparibafterpreoperativechemotherapyinpatientswithtriple-negativebreastcancer(TNBC):HoosierOncologyGroupBRE09-146.順鉑聯(lián)合或不聯(lián)合rucaparib輔助治療接受過(guò)新輔助化療的三陰性乳腺癌：HoosierOncologyGroupBRE09-146試驗(yàn)結(jié)果。15:45–15:55專家評(píng)述DiscussionTopic:PARPinhibitionforbreastcancer討論主題：PARP抑制與乳腺癌殷詠梅(Yong-MeiYin)15:55–16:00討論(Q&A)江澤飛(Ze-FeiJiang)宋爾衛(wèi)(Er-WeiSong)殷詠梅(Yong-MeiYin)16:00-16:15休息Break乳腺癌專場(chǎng)2(BreastCancerSession2)主席(Chair)：徐兵河(Bing-HeXu)、劉冬耕(Dong-GengLiu)時(shí)間(Time)專場(chǎng)(Session)講者(Speaker)16:15–16:35Abstract510Expressionofimmunologicgenesintriple-negativeandHER2-positivebreastcancerintheneoadjuvantGEPARSIXTOtrial:Predictionofresponsetocarboplatin-basedchemotherapy.新輔助治療研究GEPARSIXTO中三陰性和HER2陽(yáng)性乳腺癌的免疫基因的表達(dá)：卡鉑為根底的化療方案的療效預(yù)測(cè)。袁芃(PengYuan)Abstract511Trackingtumor-specificmutationsincirculating-freeDNAtopredictearlyrelapseaftertreatmentofprimarybreastcancer.循環(huán)DNA中腫瘤特異突變的動(dòng)態(tài)檢測(cè)與乳腺癌療后復(fù)發(fā)的早期預(yù)測(cè)。16:35–16:45專家評(píng)述：DiscussionTopic:Genomicsignaturefortriplenegativebreastcancer討論主題：三陰性乳腺癌的基因標(biāo)志物金鋒(FengJin)16:45–16:50討論(Q&A)徐兵河(Bing-HeXu)劉冬耕(Dong-GengLiu)金鋒(FengJin)乳腺癌專場(chǎng)3(BreastCancerSession3)主席(Chair)：徐兵河(Bing-HeXu)、劉冬耕(Dong-GengLiu)時(shí)間(Time)專場(chǎng)(Session)講者(Speaker)16:50–17:10AbstractLBA4FirstresultsfromthephaseIIIALTTOtrial(BIG2-06;NCCTG[Alliance]N063D)comparingoneyearofanti-HER2therapywithlapatinibalone(L),trastuzumabalone(T),theirsequence(T→L),ortheircombination(T+L)intheadjuvanttreatmentofHER2-positiveearlybreastcancer(EBC).III期ALTTO試驗(yàn)的首次結(jié)果〔BIG2-06;NCCTG[Alliance]N063D)：比較拉帕替尼單藥治療〔L〕，或曲妥珠單抗單藥治療〔T〕，或曲妥珠單抗序貫到拉帕替尼(T→L)，或曲妥珠單抗聯(lián)合拉帕替尼〔T+L〕輔助治療HER2陽(yáng)性早期乳腺癌的一年療效。劉健(JianLiu)Abstract508Efficacyofadjuvanttrastuzumab(T)comparedwithnoTforpatients(pts)withHER2-positivebreastcancerandtumors≤2cm:Ameta-analysisoftherandomizedtrastuzumabtrials.一項(xiàng)針對(duì)曲妥珠單抗隨機(jī)試驗(yàn)的薈萃分析：在腫瘤小于或等于2厘米的HER2陽(yáng)性乳腺癌患者輔助治療中使用或不使用曲妥珠單抗的療效比照結(jié)果。17:10–17:20專家評(píng)述：DiscussionTopic:OptimaladjuvanttherapyforearlyresectableHER2+ivebreastcancer討論主題：早期可手術(shù)的HER2陽(yáng)性乳腺癌患者的最正確輔助治療方案。陸勁松(Jin-SongLu)17:20–17:25討論(Q&A)徐兵河(Bing-HeXu)劉冬耕(Dong-GengLiu)陸勁松(Jin-SongLu)乳腺癌專場(chǎng)4(BreastCancerSession4)主席(Chair)：于丁(DingYu)、胡夕春(Xi-ChunHu)時(shí)間(Time)專場(chǎng)(Session)講者(Speaker)17:25–17:50AbstractLBA1Randomizedcomparisonofadjuvanttreatmentwitharomataseinhibitor(AI)exemestane(E)plusovarianfunctionsuppression(OFS)versustamoxifen(T)plusOFSinpremenopausalwomenwithhormonereceptor-positive(HR+)earlybreastcancer(BC):JointanalysisofIBCSGTEXTandSOFTtrials.比較依西美坦聯(lián)合卵巢去勢(shì)和他莫昔芬聯(lián)合卵巢去勢(shì)在絕經(jīng)前激素受體陽(yáng)性早期乳腺癌患者的輔助治療研究：IBCSGTEXT試驗(yàn)和SOFT試驗(yàn)聯(lián)合分析。廖寧(NingLiao)Abstract500Bevacizumab(Bv)intheadjuvanttreatmentofHER2-negativebreastcancer:FinalresultsfromEasternCooperativeOncologyGroupE5103.貝伐單抗在HER2陰性乳腺癌的輔助治療研究：東部腫瘤協(xié)作組織E5103研究最終結(jié)果。Abstract504Prognosticassociationsof25OHvitaminDinNCICCTGMA.21,aphaseIIIadjuvantRCTofthreechemotherapyregimens(EC/T,CEF,AC/T)inhigh-riskbreastcancer(BC).在高風(fēng)險(xiǎn)乳腺癌患者人群使用三種輔助化療方案EC/T、CEF、AC/T的III期臨床試驗(yàn)中〔NCICCTGMA.21〕，關(guān)于預(yù)后和25羥基-維生素D水平關(guān)系的臨床研究。17:50–18:05專家評(píng)述DiscussionTopic:OptimaladjuvanttherapyforearlyresectableHER2–ivebreastcancer討論主題：早期可手術(shù)的HER2陰性乳腺癌患者的最正確輔助治療方案PeterYu翻譯：張劍(JianZhang)18:05–18:10討論(Q&A)于丁(DingYu)胡夕春(Xi-ChunHu)PeterYu18:10–19:30 自助晚餐(BuffetDinner)19:00–20:30 衛(wèi)星會(huì)(Satellitesymposium)會(huì)議第二天2023年7月12日(Day2,July12,2023)8:00–8:10 主席致辭(ChairmanAddress)莫樹(shù)錦教授歡迎參加第2天會(huì)議(Welcometoday2byProf.TonyMok)肉瘤專場(chǎng)(SarcomaSession)主席(Chair)：秦叔逵(Shu-KuiQin)、潘宏銘(Hong-MingPan)時(shí)間(Time)題目(Topic)講者(Speaker)8:10–8:30Abstract10506Aphase2studyofponatinibinpatients(pts)withadvancedgastrointestinalstromaltumors(GIST)afterfailureoftyrosinekinaseinhibitor(TKI)therapy:Initialreport.普納替尼〔ponatinib〕治療酪氨酸激酶抑制劑〔TKI〕失敗后的進(jìn)展期胃腸間質(zhì)瘤〔GIST〕的II期臨床研究初步報(bào)告。楊林(LinYang)Abstract10508Long-termdiseasecontrolofadvancedgastrointestinalstromaltumors(GIST)withimatinib(IM):10-yearoutcomesfromSWOGphaseIIIintergrouptrialS0033.伊馬替尼〔IM〕在進(jìn)展期胃腸道間質(zhì)瘤〔GIST〕中的長(zhǎng)期疾病控制：來(lái)自于西南腫瘤協(xié)作組〔SWOG〕的III期臨床試驗(yàn)S0033的十年結(jié)果。8:30–8:45專家評(píng)述DiscussionTopic:WhathappentoGISTafter12yearsoftargetedtherapy討論主題：靶向治療胃腸道間質(zhì)瘤〔GIST〕十二年后現(xiàn)狀龍浩鋒(HerbertHo-FungLoong)翻譯：樊英(YingFan)8:45–8:50討論(Q&A)秦叔逵(Shu-KuiQin)、潘宏銘(Hong-MingPan)、龍浩鋒(HerbertHo-FungLoong)肺癌專場(chǎng)1(LungCancerSession1)主席(Chair)：吳一龍(Yi-LongWu)、程穎(YingCheng)時(shí)間(Time)題目(Topic)講者(Speaker)8:50-9:15Abstract8002First-linecrizotinibversuspemetrexed–cisplatinorpemetrexed–carboplatininpatients(pts)withadvancedALK-positivenon-squamousnon-smallcelllungcancer(NSCLC):resultsofaphaseIIIstudy(PROFILE1014).一線克唑替尼比照培美曲塞/順鉑或培美曲塞/卡鉑治療ALK陽(yáng)性晚期非鱗癌非小細(xì)胞肺癌：III期臨床研究結(jié)果(PROFILE1014)。周清(QingZhou)Abstract8003^Ceritinibinadvancedanaplasticlymphomakinase(ALK)-rearranged(ALK+)non-smallcelllungcancer(NSCLC):ResultsoftheASCEND-1trial.Ceritinib治療ALK陽(yáng)性晚期非小細(xì)胞肺癌：ASCEND-1研究結(jié)果。Abstract8009^ClinicalactivityofthemutantselectiveEGFRinhibitorAZD9291inpatients(pts)withEGFRinhibitorresistantnon-smallcelllungcancer(NSCLC).選擇性EGFR抑制劑AZD9291治療EGFR抑制劑耐藥的非小細(xì)胞肺癌的療效。9:15-9:30專家評(píng)述DiscussionTopic:CurrentapproachtoALK+ivelungcancer討論主題：ALK陽(yáng)性肺癌的治療策略LamKwokChi翻譯：徐崇銳(Chong-RuiXu)9:30-9:35討論(Q&A)吳一龍(Yi-LongWu)程穎(YingCheng)LamKwokChi肺癌專場(chǎng)2(LungCancerSession2)主席(Chair)：陸舜(ShunLu)、王潔(JieWang)時(shí)間(Time)題目(Topic)講者(Speaker)9:35–9:55Abstract8005Erlotinibplusbevacizumab(EB)versuserlotinibalone(E)asfirst-linetreatmentforadvancedEGFRmutation–positivenonsquamousnon-smallcelllungcancer(NSCLC):Anopen-labelrandomizedtrial.厄洛替尼聯(lián)合貝伐單抗比照厄洛替尼單藥一線治療EGFR突變的晚期、非鱗非小細(xì)胞肺癌：一項(xiàng)開(kāi)放性的隨機(jī)研究。范云(YunFan)AbstractLBA8006^REVEL:Arandomized,double-blind,phaseIIIstudyofdocetaxel(DOC)andramucirumab(RAM;IMC-1121B)versusDOCandplacebo(PL)inthesecond-linetreatmentofstageIVnon-smallcelllungcancer(NSCLC)followingdiseaseprogressionafteronepriorplatinum-basedtherapy.多西他塞聯(lián)合ramucirumab(RAM;IMC-1121B)比照多西他塞聯(lián)合撫慰劑二線治療鉑類方案進(jìn)展的IV期非小細(xì)胞肺癌：一項(xiàng)隨機(jī)、雙盲、III期研究REVEL。9:55–10:05專家評(píng)述DiscussionTopic:Asecondlookatanti-angiogenesisforlungcancer討論主題：肺癌抗血管生成治療的再次展望常建華(Jian-HuaChang)10:05–10:10討論(Q&A)陸舜(ShunLu)王潔(JieWang)常建華(Jian-HuaChang)10:10-10:25休息Break肺癌專場(chǎng)3(LungCancerSession3)主席(Chair)：王綠化(Lv-HuaWang)、盧鈾(YouLu)時(shí)間(Time)題目(Topic)講者(Speaker)10:25–10:50Abstract7501Arandomizeddoubleblindphase3trialofadjuvanterlotinib(E)versusplacebo(P)followingcompletetumorresectionwithorwithoutadjuvantchemotherapyinpatients(pts)withstageIB-IIIAEGFRpositive(IHC/FISH)non-smallcelllungcancer(NSCLC):RADIANTresults.IHC/FISH檢測(cè)EGFR陽(yáng)性的IB-IIIA期非小細(xì)胞肺癌〔NSCLC〕患者完整切除術(shù)后按期別給予或不給予輔助化療后，埃羅替尼〔E〕治療比照撫慰劑〔P〕的隨機(jī)、雙盲、III期研究：RADIANT結(jié)果。樊旼(MinFan)Abstract7502Randomizedtrialonthoracicradiotherapy(TRT)inextensive-stagesmallcelllungcancer.廣泛期小細(xì)胞肺癌胸部放療的隨機(jī)研究。Abstract7503Prophylacticcranialirradiation(PCI)hasadetrimentaleffectontheoverallsurvival(OS)ofpatients(pts)withextensivediseasesmallcelllungcancer(ED-SCLC):ResultsofaJapaneserandomizedphaseIIItrial.接受預(yù)防性腦照射〔PCI〕對(duì)廣泛期小細(xì)胞肺癌的患者總體生存有害：一項(xiàng)日本隨機(jī)III期研究的結(jié)果。10:50–11:05專家評(píng)述DiscussionTopic:StateofartmanagementofextensivestageSCLC討論主題：廣泛期小細(xì)胞肺癌治療最新進(jìn)展HeatherWakelee翻譯：楊衿記(Jin-JiYang)11:05–11:10討論(Q&A)王綠化(Lv-HuaWang)盧鈾(YouLu)HeatherWakelee婦瘤專場(chǎng)(GynecologicMalignancySession)主席(Chair)：吳令英(Ling-YingWu)、吳小華(Xiao-HuaWu)時(shí)間(Time)題目(Topic)講者(Speaker)11:10–11:35Abstract5500Arandomizedphase2trialcomparingefficacyofthecomb